...
首页> 外文期刊>Cancer Cell International >Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate
【24h】

Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate

机译:胶原蛋白介导蛋白4启动子甲基化水平可作为诊断前列腺原发性恶性淋巴瘤的潜在指标

获取原文
           

摘要

Primary malignant lymphoma of the prostate (PMLP) is prone to occur in the elderly, and it has no significant correlation with lactate dehydrogenase (LDH) and prostate specific antigen (PSA). Clinical symptoms and imaging data of PMLP remain unspecific, and its prognosis is poor. A previous result showed that collapsin response mediator protein 4 (CRMP4) promotor methylation can be used as a predictor for lymph node metastases in prostate biopsies. However, the relationship between CRMP4 promotor methylation and PMLP has not been studied. We investigated the clinicopathological features of PMLP and the significance of CRMP4 methylation in PMLP. The clinical data and diagnosis information of 10 patients with PMLP were retrospectively analyzed. The CRMP4 promotor methylation level in paraffin-embedded tissues of the 10 patients with PMLP were determined and then compared to limited prostate cancer (LPCa) and its negative lymph node tissue [LPCa-LN (−) (10 cases)] and also to metastatic prostate adenocarcinoma (mPCa) and its positive lymph node tissue [mPCa-LN (+) (10 cases)]. Methylation of the CRMP4 promotor in each group was analyzed statistically. A receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of CRMP4 methylation in PMLP. The average methylation value of CRMP4 in 10 PMLP patients, 20 cases of prostate adenocarcinoma tissue, 10 cases LPCa-LN (−) and 10 cases mPCa-LN (+) were 42.3, 30.6, 6.7 and 20.3%, respectively. A Kruskal–Wallis test showed that the difference of CRMP4 methylation was significant (X2 = 38.0, P  0.001). An ROC curve analysis found that CRMP4 methylation  40.9% could diagnose PMLP. This method had 90% sensitivity and 95% specificity under conditions of CRMP4 methylation  40.9%. The area under the curve (AUC) was 0.957. Methylation of the CRMP4 gene was significantly increased in PMLP, and it is expected to become a new predictor for PMLP.
机译:老年人原发性前列腺恶性淋巴瘤(PMLP)容易发生,并且与乳酸脱氢酶(LDH)和前列腺特异性抗原(PSA)没有显着相关性。 PMLP的临床症状和影像学数据仍不确定,其预后较差。先前的结果表明,胶原蛋白反应介质蛋白4(CRMP4)启动子甲基化可以用作前列腺活检中淋巴结转移的预测因子。但是,尚未研究CRMP4启动子甲基化与PMLP之间的关系。我们调查了PMLP的临床病理特征以及CRMP4甲基化在PMLP中的意义。回顾性分析10例PMLP的临床资料和诊断信息。确定10例PMLP患者石蜡包埋组织中CRMP4启动子甲基化水平,然后与有限前列腺癌(LPCa)及其阴性淋巴结组织[LPCa-LN(-)(10例)]和转移性进行比较前列腺腺癌(mPCa)及其阳性淋巴结组织[mPCa-LN(+)(10例)]。统计分析每组CRMP4启动子的甲基化。接收者操作特征(ROC)曲线用于分析PMLP中CRMP4甲基化的诊断价值。 10例PMLP患者,20例前列腺腺癌组织,10例LPCa-LN(-)和10例mPCa-LN(+)的CRMP4平均甲基化值分别为42.3%,30.6、6.7和20.3%。 Kruskal–Wallis检验表明CRMP4甲基化差异显着(X2 = 38.0,P <0.001)。 ROC曲线分析发现CRMP4甲基化> 40.9%可以诊断PMLP。在CRMP4甲基化> 40.9%的条件下,该方法的灵敏度为90%,特异性为95%。曲线下面积(AUC)为0.957。 PMLP中CRMP4基因的甲基化显着增加,并且有望成为PMLP的新预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号